MannKind Corporation
Health Care · Biotechnology

MannKind Corporation: Products & infrastructure

MannKind Corporation has 59 clinical trials on record, 2 under way. MannKind Corporation paid US doctors and teaching hospitals $527k in 2025, and $2.3M for research (CMS Open Payments).

Data updated Nov 22, 2026 · Back to the company report

Products

MannKind Corporation has 59 clinical trials on record, 2 under way. MannKind Corporation paid US doctors and teaching hospitals $527k in 2025, and $2.3M for research (CMS Open Payments).

59clinical trials
2trials under way
13in phase 3
$2.8Mpaid to US doctors in 2025
Payments to US doctorsCMS Open Payments - the maker's totals, no recipient
2025
general $527k · research $2.3M · 11,197 records
$2.8M
2024
general $423k · research $3.2M · 16,709 records
$3.7M
2023
general $849k · research $4.1M · 15,651 records
$5M
Food And Beverage
a kind of payment, 2025
$220k
Compensation For Services Other Than Consulting, Including S
a kind of payment, 2025
$193k
Honoraria
a kind of payment, 2025
$60k
Afrezza
a product, 2025
$445k
Clinical trialsthe studies it sponsors or works on, per ClinicalTrials.gov · and 51 more records
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
phase 2 · under way · 153 participants · Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)
May 2026
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
phase 2 · under way · 100 participants · Type 1 Diabetes Mellitus
Feb 2026
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
phase 1 · completed · 27 participants · Idiopathic Pulmonary Fibrosis (IPF)
Dec 2025
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
phase 3 · stopped or withdrawn · 132 participants · MAC Lung Disease; Treatment Refractory MAC Lung Disease; Mycobacterium Infectio…
Sep 2024
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers
phase 1 · stopped or withdrawn · 40 participants · Healthy Volunteers
May 2024
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
phase 4 · completed · 141 participants · Diabetes Mellitus, Type 1
Jul 2023
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
phase 4 · completed · 33 participants · Type 1 Diabetes
Mar 2022
Afrezza® INHALE-1 Study in Pediatrics
phase 3 · completed · 319 participants · Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sep 2021
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.